Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
Shuangshuang ZhaoMinmin ZhangQing ZhangJingjun WuHui Dai
Published in: BMC cancer (2024)
Both anlotinib alone and its combination with Bev demonstrated good efficacy and safety in the treatment of rHGG.